Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence

Ziadé, Nelly; Mallak, Iyad; Merheb, Georges; Ghorra, Pierre; Baerlecken, N.T.; Witte, Torsten; Baraliakos, Xenofon

doi:10.3389/fimmu.2019.00574

Cited by 23 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, axSpA patients may exhibit reduced frequencies of blood CD19 + CD27 + memory B-cells (6). Furthermore, several antibodies to microbial and autoantigenic targets have been observed in axSpA [reviewed by Quaden et al (7)], in particular autoantibodies against CD74 (MHC class II invariant chain) (8)(9)(10). In addition, an antinuclear antibody (ANA) titer of 1:80 or higher was present in 20% of AS patients (11).…”

Section: Introductionmentioning

confidence: 99%

CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis

et al. 2021

View full text Add to dashboard Cite

B-cells have received little attention in axial spondyloarthritis (axSpA) and for this reason their role in pathogenesis remains unclear. However, there are indications that B-cells may be involved in the disease process. Our objective was to obtain insights into the composition of the peripheral B-cell compartment of axSpA patients compared to healthy donors (HD) and patients with primary Sjögren’s syndrome (pSS), a typical B-cell-associated autoimmune disease. Special emphasis was given to CD27-negative B-cells expressing low levels of CD21 (CD21low B-cells), since this subset is implicated in autoimmune diseases with strong involvement of B-cells. Transitional B-cells (CD38hi) were excluded from the analysis of the CD27-CD21low B-cell compartment. This study included 45 axSpA patients, 20 pSS patients and 30 HDs. Intriguingly, compared to HDs the frequency of CD27-CD38lowCD21low B-cells was significantly elevated in both axSpA and pSS patients (P<0.0001 for both comparisons). The frequency of CD27-CD38lowCD21low B-cells expressing the activation-induced immune markers T-bet and CD11c was decreased in axSpA patients compared to HDs. A higher proportion of CD27-CD38lowCD21low B-cells expressed the chemokine receptor CXCR3 in axSpA compared to HDs, suggestive for active involvement of these cells in an inflammatory process. The frequency of CD27-CD38lowCD21low B-cells in axSpA patients correlated positively with age and erythrocyte sedimentation rate. Furthermore, axSpA patients with extra-skeletal manifestations (ESM) showed increased frequencies of CD27-CD38lowCD21low B-cells compared to patients without ESM. In conclusion, our findings are suggestive of active B-cell involvement in the pathogenesis of axSpA, against prevailing dogma.

show abstract

Section: Introductionmentioning

confidence: 99%

CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some studies have evaluated a promising marker, anti-CD74 antibody. 34 ○ evaluate treatment strategies, patient beliefs, and treatment adherence.…”

Section: Discussionmentioning

confidence: 99%

The treatment journey for patients with axial spondyloarthritis in North Africa and the Middle East: From diagnosis to management

Zorkany

Ali

Namas³

et al. 2020

Int J of Rheum Dis

View full text Add to dashboard Cite

Spondyloarthritis (SpA) comprises a spectrum of chronic inflammatory conditions that share common clinical features, laboratory abnormalities, and imaging features, and genetically tend to be associated with human leukocyte antigen B27 (HLA-B27). 1 The spectrum includes radiographic axial SpA (axSpA, known as ankylosing spondylitis [AS]), nonradiographic axSpA (nr-axSpA), psoriatic arthritis, inflammatory bowel disease-related arthritis, reactive arthritis, and undifferentiated SpA. 1,2 The onset of symptoms tends to occur at a relatively young age, often when patients are in their 20s. 1 The reported age at the time of initial symptom presentation in North Africa and the Middle East, including Saudi Arabia, Qatar, United Arab Emirates, Kuwait, and Egypt ranges between 23 and 32 years. 3-7 AxSpA primarily involves the sacroiliac joints and/or spine. 1 Establishing a diagnosis of axSpA, particularly at an early stage in the disease, can be challenging. 8 In 2009, the Assessment

show abstract

“…The diagnostic value of the test might, however, be higher in some regions (e.g. the Middle East and North Africa) with a low HLA-B27 prevalence among SpA patients [ 27 ].…”

Section: Which Parameters Are Relevant For the Diagnosis And Classifimentioning

confidence: 99%

Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis

Poddubnyy

2020

Rheumatology

View full text Add to dashboard Cite

In recent years, significant progress has been made in improving the early diagnosis of spondyloarthritides (SpA), including axial SpA. Nonetheless, there are still issues related to the application of classification criteria for making the primary diagnosis of SpA in the daily practice. There are substantial conceptional and operational differences between the diagnostic vs classification approach. Although it is not possible to develop true diagnostic criteria for natural reasons as discussed in this review, the main principles of the diagnostic approach can be clearly defined: consider the pre-test probability of the disease, evaluate positive and negative results of the diagnostic test, exclude other entities, and estimate the probability of the disease at the end. Classification criteria should only be applied to patients with an established diagnosis and aimed at the identification of a rather homogeneous group of patients for the conduction of clinical research.

show abstract

Added Value of Anti-CD74 Autoantibodies in Axial SpondyloArthritis in a Population With Low HLA-B27 Prevalence

Cited by 23 publications

References 26 publications

CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis

CD27-CD38lowCD21low B-Cells Are Increased in Axial Spondyloarthritis

The treatment journey for patients with axial spondyloarthritis in North Africa and the Middle East: From diagnosis to management

Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis

Contact Info

Product

Resources

About